We compare four methods for measuring cyclosporine (CyA) in plasma and whole blood of transplant patients: HPLC, RIA with a polyclonal antibody, RIA with a monoclonal antibody, and fluorescence polarization immunoassay (FPIA). The monoclonal AlA procedure correlated acceptably with HPLC, with slope = 1.21, r = 0.97, and S = ±40.1. However, the FPIA, done in three separate instruments, correlated relatively poorly with HPLC, giving slopes of 1.67, 1.51, and 2.32; correlation coefficients of 0.72, 0.43, and 0.83; and S = ±205.4, ±334.5, and ±222.4. The polyclonal AlA correlated reasonably well with HPLC, with a slope = 1.15, r = 0.90, and S,,, = ± 72.6. Values for individual patients with increases both in gamma-glutamyltransferase and creatinine showed very poor correlation between FPIA and HPLC, which suggests that metabolite cross-reactivity with FPIA is significant and unpredictable in patients with liver dysfunction coexisting with renal dysfunction. Evidently, the monoclonal AlA can be substituted for HPLC, if the therapeutic range is adjusted for the 21% higher results obtained by RIA. Cyclosporine (CyA) is now routinely used as an immunosuppressant in patients who are receiving organ transplants, but its concentrations in blood must be closely monitored because of (a) the relatively narrow therapeutic range; (b) individual patient variations in absorption, metabolism, and excretion of the drug; and (c) the risk of either nephro-or hepatotoxicity (13).1
immunoassay, an and a monoclonal antibody that specifically measures the parent drug in whole blood are used.
Because such a wide variety of methods is available for measuring CyA, there still is confusion as to which method is best suited for routine clinical application. Also, the presence of hepatic and renal dysfunction in monitored patients has not been extensively investigated. Here we present an evaluation of the methods currently available for measuring CyA. Additionally, because the metabolism of CyA and excretion of its metabolites are strongly influenced by hepatic and renal diseases, we investigated the influence of selected hepatic enzymes and creatinine on measurement of CyA by these various methods.
Materials and Methods

Specimen
collection. This study was conducted in two phases. In both we used specimens from patients who were receiving CyA as an immunosuppressant to prevent allograft rejection. In Phase 1, specimens from 57 patients were collected into two EDTA-containing collection tubes and one heparinized tube. Because of an unexplained lack of correlation among results of the various methods, we initiated a Phase 2 study, as follows. CyA was assayed in 107 whole-blood specimens collected from 52 additional patients during three months, and the corresponding plasma specimens were analyzed for creatinine (Astra; Collections were made in the morning just before the CyA was administered.
For plasma assays, whole blood was first incubated for 15 miii in a water bath at 37 #{176}C and the plasma was then separated from cells by centrifugation (750 x g, 5 mm). Specimens were stored at -20 #{176}C before analysis.
" equipped with a 50 x 4.5 mm Superb LC1 column (Supelco, Bellefonte, PA 16823). The temperature of the column was maintained at 70#{176}C. The flow rate was 1.0 mL/min.
Radioimmunoassay.
CyA in heat-treated plasma was measured with the Sandoz method (Sandoz Pharmaceuticals) according to the manufacturer's protocol(8). This RIA involves use of a polyclonal antibody and [3Hldihydro-cyclosporin as tracer. In brief, a 0.05-mL sample, standard, or control is prediluted in a Tris/monolaurate buffer, then treated with 0.1 mL of tracer solution and 0.1 mL of antiserum. This mixture is incubated for 2 h, after which charcoal is added to separate the non-antibody-bound moiety. After centrifugation at -0.4 #{176}C, the supernatant fluid is decanted into Picofluor-30 scintillation cocktail and its radioactivity is counted for 1 min in a beta counter (Packard Instrument Co., Meriden, CT 06450).
The second RIA method we used to measure CyA was the Cyclo-Trac SP (Incstar, Stillwater, MN 55082), in which an '251-labeled CyA analog is used as tracer. We hemolyzed each whole-blood specimen by adding methanol, vortexmixing for 15 s, then centrifuging (1600 x g, 20-25 #{176}C) for 5 mm. We then treated 50 L of extracted sample with 0.1 mL of tracer followed by 1.0 mL of the antibody solution.
After 1 h of incubation, the reaction tubes were decanted, drained thoroughly, and the remaining radioactivity was counted for 2 mm in a scintillation counter (20/20 Multiwell; Iso-Data, Rolling Meadows, IL 60008).
Fluorescence polarization immunoassay.
In the Phase 1 study, split whole-blood specimens were assayed for CyA in two TDx FPIA instruments (Abbott, Irving, TX 75038) located in two separate laboratories and operated by different technologists.
In the Phase 2 study, a third TDx was acquired and used in only one laboratory. The CyA method Table 1 In addition to Lotus, we used another software package (Statgraphics Statistical Graphics System, Rockville, MD 20852) for some statistical analyses and graphics. For simple linear-regression analyses we used the Pearson product-moment correlation procedure, and all variance results were obtained by utilizing the one-way analysis of variance procedure. Values for y-intercept and slope for each linear curve fit were calculated, as well as the correlation coefficient (r), Student's t distribution, the F-ratio, the probability bevel (P), and the standard error of regression (Si).
Precision. Precision studies on each method were performed by repetitive analyses of control material(s).
Results
The four assays compared. In the Phase 1 study, results by the two RIA methods and two TDx instruments were compared with those by the HPLC method, which we treated as a "reference" (comparison) method (Table 1) . Similarly, in the Phase 2 study, the HPLC method was again selected as the reference for statistical comparison with the other three methods. Table 2 are given in Figure 1 .
GGT vs "test method"/HPLC ratios. For the two RIA 37 methods and the FPIA method, we compared the GGT 37 values with the corresponding CyA ratios, computed by 37 dividing each CyA value by the HPLC value obtained for 16 the same specimen (Table 3) . GGT values 55 UIL, along with those 40 U/L, were also compared with their correspendingFPIAJHPLC ratios (Table 3) 
Discussion
Values for CyA by the various methods used in this study agree poorly. As depicted in Table 1 studies (3,10,11 ). These observations strongly suggest that the mouse monoclonal antibody used in the Incstar method does indeed measure CyA specifically with no significant interferences from metabolites. Moreover, Incstar uses an '251-labeled cyclosporine analog as a tracer, thus eliminating the need for beta counting as described above in the Sandoz method. The Incstar method is relatively rapid (1 h incubation time) and highly reproducible, making the method an attractive alternative to HPLC in transplantation centers interested in using an assay specific for CyA. Except for the Sandoz method (Phase 2), the test methods gave higher results than did the HPLC ( Table 1) (Table 1 and Figure   2 ). This random scatter was not observedin the Incstar vs HPLC comparison, for which
Sy,x ranged from 40.1 to 58.6 in Phases 2 and 1, respectively. The Sandoz method showed relatively low random scatter about the regression line as well, with Sy,x = 71.6 and 55.9. Moreover, the y-intercepts for both the Sandoz and Incstar methods were relatively low and hence acceptable.
A recent study (12) found that Incstar results overestimated CyA concentrations in plasma, as compared with their in-house standard HPLC results, by an average of 23%. That study also reported discrepant results for several patients by the Incstar assay. Although we observed that Incstar gave results -21% higher than HPLC for wholeblood samples, we did not observe discrepant Incstar results in any of the patients in our study. The apparent lack of correlation with TDx and other routinely used methods for measuring CyA has been reported (4,5); however, we found that the degree of discrepant results in selected patients could in fact lead to inappropriate therapeutic interventions.
To illustrate this point, we examined CyA results in patients with increased concentrations of GGT, an enzyme commonly associated with liver dysfunction. GGT values >55 U/L were considered above normal (as measured with the flu Pont aca) (13). We reasoned that these patients might be predisposed to have increased concentrations of CyA metabolites in plasma, owing to the inability to excrete these normally through the biliary system. Furthermore, we reasoned that, in patients with increased blood concentrations of creatinine, renal dysfunction would slow the excretion of TDUPI.C0.00 this we conclude that metabolites that appear in plasma because of liver dysfunction are rapidly excreted in patients without renal dysfunction. Furthermore, in patients with no apparent liver dysfunction (i.e., normal concentrations of GOT), CyA metabolites would not be present in the plasma because of their normal excretion through the biiary system.
Also indicated
in Table 2 is the remarkable variation in the TDx results for patients with an increase of either GOT or creatinine. Although some have argued that TDx can be effectively used to monitor cyclosporine within a patient (14), we consider it impossible, on the basis of these data, to establish a universal therapeutic range between patients or for a particular patient. Regression-line slopes for TDx vs HPLC range from 2.7 in patient 2, with good correlation (r = 0.97), to 1.2 in patient 6, with poor correlation (r = 0.29). Apparently, metabolites in diseased patients do not interfere with the TDx method in a predictable manner, even within individual patients. On the other hand, with the Sandoz method, which also measures metabolites, we did not observe discrepant CyA results, even in patients with increases in both GOT and creatinine.
To illustrate the degree of influence of GOT on variability of the various methods, we plotted GOT vs the ratio of each method to HPLC (see Table 3 ). The Incstar and Sandoz methods showed no significant correlation between the ratio and GOT (r = 0.07 and 0.18, P <0.05), whereas the TDx method showed a statistically significant relationship between GOT and the cyclosporine ratio (n = 83, r = 0.43, P >0.00 1). Figure 3 shows the regression-line plot of GOT values against corresponding TDxJHPLC ratio values. Similar comparisons for the enzymes AST and ALKP and their corresponding test methodfHPLC ratio values showed no significant correlations.
To further support the relationship of GOT concentrations to variability in TDx results for CyA, we explored the correlation of TDxIHPLC ratios for patients with abovenormal GOT concentrations (i.e., 55 UIL) and for patients with low to normal GOT concentrations (Table 3) . Patients with above-normal GOT showed significant correlation between this ratio and GOT (r = 0.58, P = 0.00 1), whereas those with low to normal GOT concentrations did not (r = 0.20, P = 0.18).
We conclude that the Incstar whole-blood assay gives excellent correlation with the HPLC method. However, our studies indicate that the TDx method may not be acceptable for monitoring CyA concentrations, especially in patients with liver dysfunction coexisting with renal dysfunction. We suggest that laboratories using the TDx method should also test for GOT and creatinine concentrations and, when those are above normal, establish the actual value for CyA in blood by a more reliable method, i.e., HPLC or Incstar.
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